EUROIMMUN to Use Scienion Arrayer for Biochip Development and Production
Complete the form below to unlock access to ALL audio articles.
Scienion AG has announced that EUROIMMUN AG has purchased Scienion’s sciFLEXARRAYER technology to develop multiplexed diagnostic products and to produce new test formats.
EUROIMMUN is one of the world’s leading manufacturers of medical laboratory diagnostics with a focus on test systems for the determination of various antibodies in patient serum in the diagnosis of autoimmune diseases, infectious diseases and allergies.
The Lübeck, Germany-based company with about 1000 employees worldwide recently decided, after evaluating several suppliers, to use Scienion’s non-contact sciFLEXARRAYER printing platform for both R&D and production purposes of new multiplexed diagnostic products.
Dr. Ulf Steller, Head of Microarray Division at EUROIMMUN AG, gives several reasons for choosing Scienion’s sciFLEXARRAYER: “Having compared different dispensers, we regard the sciFLEXARRAYER family as the most advanced DNA and protein printing systems currently available. Performing extensive pilot studies at Scienion convinced us of the technology and was a great aid in taking this important decision. For us, the flexibility of the system is a key advantage, as we manufacture different types of diagnostic tests. We expect that the integration of Scienion’s scalable technology will help us adapt production processes to the throughput we need in the following years.”
Dr. Holger Eickhoff, CEO of Scienion AG, states: “Dispensing and deposition of reagents in the picoliter to nanoliter range has become crucial for Next-Generation Diagnostic Products. Scienion is well-positioned to enable the dispensing of any kind of content to any kind of surface and this is a strategic advantage for the continuously growing market of multiplexed assays in the in-vitro diagnostics (IVD) field. EUROIMMUN has developed excellent products and we have been monitoring the strong expansion of the company during the past years. I am sure EUROIMMUN will not only benefit from using our sciFLEXARRAYER technology in R&D, but also exploit its advantages as a reliable production platform to further grow in the IVD market.”
